Clinical Trial

Aflibercept and Bevacizumab for Diabetic Maculopathies

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include: * Functional changes: The visual outcomes achieved by testing visual acuity * Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-02-22; most recent amendment 2025-09-18.
Trial Details
NCT Number NCT06850571
Lead Sponsor Al-Mustansiriyah University
Collaborators: Baghdad Medical City
Conditions Diabetic Maculopathy
Enrollment 102 participants
Start Date 2025-02-20
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-19